Durvalumab (MEDI4736) and Olaparib (AZD2281) for treatment of biochemically recurrent prostate cancer in men predicted to have a high neoantigen load: A pilot study

Principal Investigator

Alexandra Sokolova

Study Purpose

The purpose of this research is to see whether the combination of durvalumab and olaparib can help lower PSA in males who have a rising PSA after surgery or primary radiation therapy for prostate cancer, and to see whether durvalumab and olaparib will reduce or delay the prostate cancer recurring.

Medical Condition(s)

Biochemical relapse (BCR) prostate cancer

Eligibility Criteria

Eligibility criteria include but are not limited to the following:

- Must have received either radiation therapy and / or prostatectomy for prostate cancer

- Must not have metastatic disease
- Must not have had prior treatment with a PD1 or PD-L1 inhibitor, including durvalumab
- Must not have had prior treatment with a PARP inhibitor, including olaparib
- Must not have history of leptomeningeal carcinomatosis
- Must not have myelodysplastic syndrome / acute myeloid leukemia

Age Range

18 - NA

Healthy Volunteers Needed


Duration of Participation

Study participation lasts approximately 24 months, with follow-up exams every 3 months for at least 2 years. This study also includes an optional long-term follow-up portion which allows the study team to follow participant's health for up to 5 years.

Minors Included



Call the clinical Trials Information Line at (503) 494-1080 or email


Recruitment End


Compensation Provided


Go Back